Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report.
Encorafenib (Braftovi) is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, in combination with binimetinib (Mektovi). According to the product label […]
» Read more